MSD
Clinical Trials
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.
CLINICALTRIALS.GOV IDENTIFIER
NCT05007106
EudraCT Number
2021-001009-56
EU CT Number
2023-505284-36
When you talk with your doctor or clinical trial team member, please have the trial identifier number available.
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Cholangiocarcinoma, Endometrial Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Hepatocellular Carcinoma, Ovarian Neoplasms, Squamous Cell Carcinoma Of Head And Neck, Stomach Neoplasms, Triple Negative Breast Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms
Age Range
18+
Sex
All
Current trial phase
In Phase 2 trials, researchers try to find out if a treatment works in about 100 to 500 participants – usually people who have the health condition the treatment is intended to treat. In vaccine trials, the participants are usually healthy. Phase 2 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial start and end dates
Sorry, there are no locations found.
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.
If you are considering joining a clinical trial, first learn as much as you can about:
Talk to your doctor about the clinical trial before you decide to join.
Read our “What to Consider” page for more questions to ask and think about